PACIRA BIOSCIENCES, INC. Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt
PACIRA BIOSCIENCES, INC. (PCRX) reported Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt of -$233.00 thousand for the 6-month period ending 2019-06-30, per its 10-Q filed 2020-08-06.
Discontinued › Shareholders' Equity › Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments
us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt · last filed 2020-08-06
- PACIRA BIOSCIENCES, INC. adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2017-06-30 was $0.00.
- PACIRA BIOSCIENCES, INC. adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2017-03-31 was $70.93M.
- PACIRA BIOSCIENCES, INC. adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2016-12-31 was $0.00.
- PACIRA BIOSCIENCES, INC. adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2016-09-30 was -$2.00K.
- PACIRA BIOSCIENCES, INC. adjustments to additional paid in capital, equity component of convertible debt for fiscal 2016 was -$2.00K.
- PACIRA BIOSCIENCES, INC. adjustments to additional paid in capital, equity component of convertible debt for fiscal 2015 was -$4.10M.
- PACIRA BIOSCIENCES, INC. adjustments to additional paid in capital, equity component of convertible debt for fiscal 2013 was $23.96M.
| Period end | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 3 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 6 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 9 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 12 month |
|---|---|---|---|---|
| 2019-06-30 | -$233.00K 10-Q · filed 2020-08-06 | |||
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | $70.93M 10-Q · filed 2017-08-02 | $70.93M derived: sum of 3 quarters · filed 2019-02-28 | $70.93M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-03-31 | $70.93M 10-Q · filed 2017-05-04 | $70.93M derived: sum of 2 quarters · filed 2019-02-28 | $70.93M derived: sum of 3 quarters · filed 2019-02-28 | $70.93M derived: sum of 4 quarters · filed 2019-02-28 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | -$2.00K derived: sum of 2 quarters · filed 2019-02-28 | -$2.00K derived: sum of 3 quarters · filed 2019-02-28 | -$2.00K 10-K · filed 2019-02-28 |
| 2016-09-30 | -$2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02 | -$2.00K derived: sum of 2 quarters · filed 2017-08-02 | -$2.00K 10-Q · filed 2016-11-02 | -$2.00K derived: sum of 4 quarters · filed 2018-02-28 |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | $0.00 10-Q · filed 2017-08-02 | $0.00 derived: sum of 3 quarters · filed 2018-02-28 | $0.00 derived: sum of 4 quarters · filed 2018-02-28 |
| 2016-03-31 | $0.00 10-Q · filed 2017-05-04 | $0.00 derived: sum of 2 quarters · filed 2018-02-28 | $0.00 derived: sum of 3 quarters · filed 2018-02-28 | |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | $0.00 derived: sum of 2 quarters · filed 2018-02-28 | -$4.10M 10-K · filed 2018-02-28 | |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-27 | -$4.10M 10-Q · filed 2015-10-27 | ||
| 2015-06-30 | -$4.10M 10-Q · filed 2015-07-30 | |||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $0.00 derived: sum of 2 quarters · filed 2016-02-25 | $0.00 derived: sum of 3 quarters · filed 2016-02-25 | $23.96M 10-K · filed 2016-02-25 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-31 | $0.00 derived: sum of 2 quarters · filed 2013-10-31 | $23.96M 10-Q · filed 2013-10-31 | |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $23.96M 10-Q · filed 2013-08-06 | ||
| 2013-03-31 | $23.96M 10-Q · filed 2013-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |